HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

CRISPR Therapeutics AG

2
Articles
Primary Subject
Top Role
Mar 24, 2026
First Mention
Mar 28, 2026
Last Mention
3.65
Relevance Score

Coverage Timeline

March 2026
CRISPR in the Real World: Vertex and CRISPR Therapeutics Shake Up Rare Disease Economics with Exa-cel The Week Primary Subject
Mar 28, 2026
Vertex and CRISPR Therapeutics didn’t just win the FDA’s nod for exa-cel, their CRISPR-based sickle cell therapy, they made a statement with the $2.2 million list price.
CRISPR Therapeutics’ CS37 in Hemophilia B: Breakthrough Candidate or Regulatory Gamble? Pipeline Primary Subject
Mar 24, 2026
CRISPR Therapeutics’ investor decks for CS37 don’t bury the lede.
Related Companies
Cigna Corporation
2 shared
CSL Limited
1 shared
Beam Therapeutics Inc.
1 shared
Editas Medicine, Inc.
1 shared
Intellia Therapeutics, Inc.
1 shared
Centers for Medicare and Medicaid Services
1 shared
GSK plc
1 shared
Vertex Pharmaceuticals Incorporated
1 shared
Blue Cross Blue Shield
1 shared
BioMarin Pharmaceutical Inc.
1 shared